Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe
, french MedTech start up, leads the new booming
category of Digital therapeutics with its revolutionary « at home «
neurofeedback, to train the brain and cure neuropsy disorders without
Co-founder INRIA-IT2 , existing shareholders and now HARA , which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour.
Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in
Rennes are computing real time signaling softwares. The neurofeedback
technique is non invasive, at home and without drugs. MENSIA
treats ADHD, Attention Deficit Disorders with or without
Hyperactivity, children and adolescents. This unique medical device is a
therapeutic video game on an interactive tablet connected to the brain
activity. Children learn to control their attention by exercising 3
times a week during 4 months of treatment. Visual feedback given during
the game, allows the children to learn, control and create automatisms.
Six years of R&D with 12 $millions invested, including the last largest
clinical multicentric trial never ever made, NEWROFEED-Koala
successfuly lead to the grant of a CE mark class IIa in Europe. Kick
start of the sales in March for France.
37 health points of care from french national partner HOMEPERF , delivers family training for home use of Koala. The device is prescribed and ordered directly on the website. Family received their Mensia Koala at home : all items ready to use for 4 month treatment, with webportail supervision. Children benefit from significant reduction of their attention deficit and or hyperactivity with long lasting effects. Benefit/Risk ratio is extremely favorable and no adverse event compared to the amphetamines drugs (Ritaline).
Michel du Peloux , CEO of Mensia Technologies : « We are proud to deliver the first worldwide digital therapeutic device to treat ADHD with a Class IIa registration for medical scripts and follow up all over Europe. Far from neurogaming, we have 5 patents, randomised clinical trials and state of the art expertise in brain computer interface. Our pipeline of « at home neurofeedback » is promising : resistant chronic low back pain despite opiods, is our next medical device. Mensia Technologies initiates now the next tour for a serie A of 20 M$ aiming to the USA deployement.
About Mensia Technologies : https://www.mensia.com
About Mensia Koala : https://www.mensia-koala.com ,
About HARA : http://health-angels-ra.com/actualites/
About clinical study : http://www.newrofeed.com/
About INRIA : http://it-translation.fr/projets/fonds/
About BPI Rennes : https://www.bpifrance.fr/Contactez-nous/Direction-regionale-Rennes
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CT-ISAF-MANAGEMENT21.11.2018 00:02 | Pressemeddelelse
Prominent Coalition of World Class International and Danish Law Firms and ISAF Management Company Proceed with Investor Lawsuit against Danske Bank
UAE-MINISTRY-OF-INTERIOR20.11.2018 23:30 | Pressemeddelelse
Saif bin Zayed Witnesses Endorsement of Abu Dhabi Declaration by Religious Leaders at Wahat Al Karama
NY-GUY-CARPENTER20.11.2018 18:48 | Pressemeddelelse
Guy Carpenter Names Ross Howard Vice Chairman
IDEMIA20.11.2018 18:33 | Pressemeddelelse
IDEMIA Will Present Its 2018 Quarterly Financial Results to Investors on November 21, 2018
OCP-S.A.20.11.2018 18:02 | Pressemeddelelse
OCP Announces Date of Third Quarter 2018 Earnings
ARCH-INSURANCE20.11.2018 16:52 | Pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum